Search
Novavax Inc
NVAXAdd to Watchlist
9.135USD
+0.135+1.50%
Market hours （ET）Quotes delayed by 15 min
1.50BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+1.50%
5 Days
-0.71%
1 Month
-0.81%
6 Months
+34.34%
Year to Date
+35.94%
1 Year
+44.77%
Key Figures
9.150Open
9.290High
225.73KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.14%Turnover Ratio
9.000Prev. Close
9.107Low
1.66MTurnover
LossP/E Static
-10.38P/B
0.00%Div Yield TTM
-7.52%ROA
11.97052wk High
0.68Volume Ratio
-187.50MNet Profit
164.42MShares
-0.5605EPS TTM
2.42Beta
-347.64%ROE
6.13052wk Low
2.03%Amplitude
78.00%Gross Margin
1.50BMarket Cap
-0.60Reward/Risk
3.80%Risk Rate
TradingKey Stock Score of Novavax Inc
Currency: USD Updated: 2026-06-23Key Insights
Novavax Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 62 out of 389 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 14.11.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Novavax Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Novavax Inc Highlights
StrengthsRisks
Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Undervalued
The company’s latest PE is -16.06, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 128.09M shares, increasing 5.38% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 30.83K shares of this stock.
Analyst Rating
Based on
9
analysts
Hold
Current Rating
14.111
Target Price
+56.79%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Novavax Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Novavax Inc Info
Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.
Ticker SymbolNVAX
CompanyNovavax Inc
CEOJacobs (John C)
Websitehttps://www.novavax.com/?locale=US
Related Instruments
+1.83%
+1.14%
+1.67%
+0.67%
+1.59%
+0.78%
+1.52%
-0.22%
+1.70%
+1.36%
+1.49%
+1.75%
-0.20%
+0.55%
+1.03%
0.00%
+1.54%
+1.08%
+2.24%
+0.25%Popular Instruments
69.869
-3.076 (-4.22%)
295.405
+1.105 (+0.38%)
200.392
+0.352 (+0.18%)
4031.500
-79.250 (-1.93%)
640.570
-30.180 (-4.50%)
1938.060
-25.540 (-1.30%)
1040.610
-11.160 (-1.06%)
350.945
+4.815 (+1.39%)
61310.020
-1130.680 (-1.81%)
383.250
+1.640 (+0.43%)
FAQs
What is the current price of Novavax Inc (NVAX)?
The current price of Novavax Inc (NVAX) is 9.00.
What is the symbol of Novavax Inc?
The ticker symbol of Novavax Inc is NVAX.
What is the 52-week high of Novavax Inc?
The 52-week high of Novavax Inc is 11.97.
What is the 52-week low of Novavax Inc?
The 52-week low of Novavax Inc is 6.13.
What is the market capitalization of Novavax Inc?
The market capitalization of Novavax Inc is 1.48B.
Is Novavax Inc (NVAX) currently rated as Buy, Hold, or Sell?
According to analysts, Novavax Inc (NVAX) has an overall rating of signal_hold, with a price target of 14.11.
What is the Earnings Per Share (EPS TTM) of Novavax Inc (NVAX)?
The Earnings Per Share (EPS TTM) of Novavax Inc (NVAX) is 2.72.
